CD33xCD3 Bispecific Antibody in AML
This study involves taking a study drug called CD33xCD3 bispecific antibody. The overall goal of this study is to see if CD33xCD3 bispecific antibody is a safe treatment for patients with relapsed or refractory acute myeloid leukemia (AML) and to learn how it targets AML cells. The study will enroll male and female patients between the ages of 2 and 21 years of age.